ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Conferess Ok $10.9 Bil. NIH Bidget, OAM to Get $3.5 Million

October 15, 1993

In Brief: Frozen Panels Available to Evaluate diagnostic Assays; Panel to Meet at Johns Hopkins April 22

March 15, 1985

NCI Staff Discusses New Guidelines for Core Grant Reviews, Comprehensiveness

July 24, 1992

US Oncology Renegotiates Agreements To Operate Under Net Earnings Model.

March 30, 2001

Oklahoma Cancer Center Recruits Four Professors.

June 15, 2001

GM Downsizes “Nobel Prize” For Cancer; Bristol Ends Medical Research Grants and Awards Program.

June 23, 2006